Novel biological therapies, including monoclonal antibodies for tumor necrosis factor (TNF), are promising; however, a subgroup of IBD patients who are non-responsive, develop adverse reactions, and/or are at risk of developing secondary infections is further complicating the management of IBD [18]. Here, TNF is linked to infection.